CAR-T cell therapies have been a game-changer for cancer treatment. However, there is room for improvement as heterogeneous antigen expression leads to tumor relapse. Additionally, CAR-T cell therapies have underperformed in solid tumors due to immunosuppressive microenvironments. In this webinar brought to you by IsoPlexis, Jessica Morris from Baylor College of Medicine will discuss two strategies for improving the efficacy of CAR-T cell therapies in leukemia and solid tumors.
Topics to be covered
- Increasing the targeting capabilities of CAR-T cells to multiple tumor-associated antigens
- Mechanisms of T cell activation and deactivation
Meet the speaker
Center for Cell and Gene Therapy
Baylor College of Medicine
Texas Children's Hospital